EVS Glaucoma Therapeutics Closes Investment with CIT GAP Funds

EVS Glaucoma Therapeutics, a Herndon-based spinout of Euclid Vision Systems that develops a sustained delivery system for glaucoma medication, closed an investment with the Center for Innovative Technology’s GAP Funds.

The amount of the funding was not disclosed.

The company intends to use the funds to pursue further development of its delivery system.

Led by Michael Ross, CEO, EGT develops an implantable, bio-degradable, collagen-based drug delivery system for Latanoprost, the leading prescribed glaucoma medication.



Join the discussion